Loading organizations...
§ Venture Capital · Beijing, Beijing, China
Investment firm funding life sciences, pharmaceuticals, and biotech, including organ-on-a-chip technology.
Key people at Bayland Capital.
Bayland Capital is an investment firm specializing in global healthcare and life sciences. As a corporate venture capital arm backed by Pharmaron, it strategically invests in innovative companies developing advanced medicines, medical devices, and biotechnologies. The firm leverages deep industry expertise supporting advancements within its portfolio.
Established in 2019, Bayland Capital was co-founded by Yuexing Su, a Founding Partner. Its inception stemmed from recognizing substantial biomedicine opportunities and a strategic vision to integrate financial backing with industrial experience. This approach enables the firm to provide both capital and synergistic support to its investees.
Bayland Capital primarily serves innovative life science companies seeking growth capital and strategic guidance. Its vision is to advance global healthcare by fostering the development of novel therapies and medical technologies. The firm aims to contribute to the biotechnology landscape through impactful investments, addressing critical medical needs.
Key people at Bayland Capital.
Bayland Capital has 3 tracked investments across 3 companies. The latest tracked deal is $14.0M Series B in PureID Medical Technology in November 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 11, 2022 | PureID Medical Technology | $14.0M Series B | Legend Capital | — |
| Nov 10, 2022 | Pure Global | $13.8M Series B | Legend Capital | — |
| Nov 18, 2020 | Wuxi Biortus Biosciences | $15.0M Series A | Bayland Capital | — |